PATENT REJECTED BUT PAR SILENT

Something is very wrong here. PR revved up the the importance of this patent in an ASX Announcement when it was filed, but now that they have received final rejection, there is dead silence. This rejection clearly meets the ASX criteria for materiality and full disclosure. If the Board no longer thinks this patent is important, it at least needs to tell us why. When the new CEO arrives, he/she needs to give first priority to improvement in communications to shareholders.

UNITED STATESPATENT AND TRADEMARK OFFICE

United States ofAmerica

ApplicationNumber16/636,545

Application Date 06.08.2018

Applicants:Krishnan, Rennie

Publication Number 20200246374

Publication Date 06.08.2020

TREATMENT OFBONE MARROW PATHOLOGIES WITH POLYSUFATED POLYSACCHARIDES” ”

US Patent office issued a FINALREJECTION NOTICE (per 35 USC § 112) & (35 USC § 103) on all 33 claims in USPatent 16/636.545.
Examiner's conclusions:
"Nothing novel & nothing patentable”

“Prior Art” (noting inter alia Ghosh& Felson publications on the links between BMELs, pain and OA and that PPSis a disease-modifying drug for OA)

“Objections to specifications” (flawed claims)